Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN92669260
ISRCTN92669260
Completed
Not Applicable

Randomised trial of two schedules of chemotherapy of the same dose/time intensity in untreated small cell lung cancer (SCLC) of poor prognosis

K Co-ordinating Committee for Cancer Research (UKCCCR)0 sites0 target enrollmentJuly 1, 2001
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsung (small cell)CancerLung (small cell)

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
ung (small cell)
Sponsor
K Co-ordinating Committee for Cancer Research (UKCCCR)
Status
Completed
Last Updated
11 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 1, 2001
End Date
TBD
Last Updated
11 years ago
Study Type
Interventional

Investigators

Sponsor
K Co-ordinating Committee for Cancer Research (UKCCCR)

Eligibility Criteria

Inclusion Criteria

  • •1\. Histologically or cytologically proven small cell carcinoma of the lung
  • •2\. Aged 75 or under
  • •3\. Extensive disease and poor prognosis, ie Eastern Cooperative Oncology Group (ECOG) performance status 2 or 3 and/or alkaline phosphatase \>1\.5 upper limit of normal range
  • •4\. Adequate renal function
  • •5\. No previous malignancy, except non melanomatous skin cancer in the preceding 3 years
  • •6\. No previous chemotherapy or radiotherapy, except for emergency radiotherapy for superior vena cava obstruction
  • •7\. No medical contraindications to treatment

Exclusion Criteria

  • •Not provided at time of registration

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
A Randomised Trial of Two Chemotherapy Regimens in the Treatment of Operable Osteosarcoma (Doxorubicin-Cisplatin versus Methotrexate-Vincristine-Doxorubicin plus Doxorubicin-Cisplatin plus Bleomycin-Cyclophosphamide-Dactinomycin)Bone cancerCancerOsteosarcoma
ISRCTN11824145Medical Research Council (MRC) (UK)400
Active, not recruiting
Not Applicable
A Randomized Phase II Study of two chemotherapy regimens, Pemetrexed-Carboplatin, and Gemcitabine-Vinorelbine, in Anthracycline and Taxane Pretreated Advanced Breast Cancer Patients - NDWomen with histologic or cytologic diagnosis of advanced breast cancer, who have received one prior chemotherapy containing anthracyclines as neo adjuvant or palliative 1st-line treatment and one prior chemotherapy containing taxanes as neo adjuvant or palliative 1st-line treatment.MedDRA version: 8.1Level: LLTClassification code 10055113Term: Breast cancer metastatic
EUCTR2006-000441-19-ITELI LILLY160
Active, not recruiting
Not Applicable
A randomised Phase II study of two chemotherapy regimens, Pemetrexed-Carboplatin, and Gemcitabine-vinorelbine, in Anthracycline and Taxane pretreated Advanced Breast cancer patients.advanced breast cancerMedDRA version: 8.0Level: LLTClassification code 10006285
EUCTR2006-000441-19-DEEli lilly and Company Limited144
Completed
Phase 2
Randomized phase II study comparing chemotherapy led by using the classification of primary tumor origin with empirical chemotherapy for patients with unknown primary cancer .
JPRN-UMIN000001919Ministry of Health, Labour and Welfare scientific research Nakagawa squad120
Active, not recruiting
Not Applicable
Strain sUrveillance during Chemotherapy for improving Cardiovascular OUtcomes
ACTRN12614000341628Menzies Research Institute Tasmania331